• Explore /
  • Poster
  • / A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors.

A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors.

Abstract Video & Slides Poster

Authors

null

Jacob Sands

Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Jacob Sands , Sara M. Tolaney , Naoto Tada Ueno , Alexander I. Spira , Noboru Yamamoto , Yelena Y. Janjigian , Yoichi Naito , Senthil Damodaran , Funda Meric-Bernstam , Shanu Modi , Peter C. Enzinger , Avani Shah Mohapatra , Yuka Iko , Siwen He , Keiko Nakajima , Kohei Shitara

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT06244485

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS4180)

DOI

10.1200/JCO.2024.42.16_suppl.TPS4180

Abstract #

TPS4180

Poster Bd #

160a

Abstract Disclosures

Similar Posters

First Author: Zhi Peng

First Author: Yoon-Koo Kang

First Author: Shubham Pant

First Author: Jin Li